<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Nanoparticle drug delivery &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/nanoparticle-drug-delivery/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 13 Jan 2026 07:33:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Nanoparticle drug delivery &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Hesperidin Nanoparticles Boost Kidney and Cancer Defense</title>
		<link>https://bioengineer.org/hesperidin-nanoparticles-boost-kidney-and-cancer-defense/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 Jan 2026 07:32:39 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Antitumor Effects]]></category>
		<category><![CDATA[Ehrlich Ascites Carcinoma]]></category>
		<category><![CDATA[Hesperidin Nanoparticles]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Renal protection]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hesperidin-nanoparticles-boost-kidney-and-cancer-defense/</guid>

					<description><![CDATA[In a significant breakthrough that merges the fields of oncology and nephrology, researchers have unveiled promising therapeutic potential of hesperidin nanoparticles in combating Ehrlich ascites carcinoma while simultaneously protecting renal function. This pioneering study, recently published in Medical Oncology, explores the multifaceted mechanisms by which these nanoparticles exert antitumor efficacy coupled with renal protection, offering [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316394</post-id>	</item>
		<item>
		<title>Nanotechnology Revolutionizes Placental Cancer Diagnosis and Treatment</title>
		<link>https://bioengineer.org/nanotechnology-revolutionizes-placental-cancer-diagnosis-and-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 29 Oct 2025 07:42:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Nanotechnology in oncology]]></category>
		<category><![CDATA[non-invasive diagnostics]]></category>
		<category><![CDATA[placental cancer diagnosis]]></category>
		<category><![CDATA[targeted cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanotechnology-revolutionizes-placental-cancer-diagnosis-and-treatment/</guid>

					<description><![CDATA[In the rapidly evolving landscape of oncology, the integration of nanotechnology has opened promising avenues for the diagnosis and treatment of a spectrum of cancers. Among these, placental cancers, notably choriocarcinoma and placental site trophoblastic tumor, represent a critical area where early detection and targeted therapy are paramount. Recent advances spearheaded by researchers Barik and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">288217</post-id>	</item>
		<item>
		<title>Lenalidomide Enhances Melarsoprol-Induced cGAS-STING Immunotherapy Against Hepatocellular Carcinoma</title>
		<link>https://bioengineer.org/lenalidomide-enhances-melarsoprol-induced-cgas-sting-immunotherapy-against-hepatocellular-carcinoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 28 Oct 2025 16:31:20 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Biomimetic nanoparticle delivery]]></category>
		<category><![CDATA[cGAS-STING immunotherapy]]></category>
		<category><![CDATA[cGAS-STING pathway activation]]></category>
		<category><![CDATA[hepatocellular carcinoma immunotherapy]]></category>
		<category><![CDATA[hepatocellular carcinoma treatment]]></category>
		<category><![CDATA[Lenalidomide-Melarsoprol combination]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[TNF-α modulation]]></category>
		<category><![CDATA[Tumor microenvironment modulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lenalidomide-enhances-melarsoprol-induced-cgas-sting-immunotherapy-against-hepatocellular-carcinoma/</guid>

					<description><![CDATA[Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer and represents a formidable global health challenge, with over 680,000 new cases diagnosed every year and a staggering 620,000 fatalities. The pernicious nature of HCC is compounded by the liver’s intrinsic immunological environment, which favors immune tolerance rather than activation. This tolerance, combined [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287862</post-id>	</item>
		<item>
		<title>Nanoparticle Bevacizumab Improves Retinopathy in Mice</title>
		<link>https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 21:40:53 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Anti-VEGF Therapy]]></category>
		<category><![CDATA[Intravitreal Drug Delivery]]></category>
		<category><![CDATA[Nanoparticle Bevacizumab]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Ocular Nanomedicine]]></category>
		<category><![CDATA[pediatric ophthalmology advancements]]></category>
		<category><![CDATA[Retinopathy of Prematurity]]></category>
		<category><![CDATA[retinopathy of prematurity treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nanoparticle-bevacizumab-improves-retinopathy-in-mice/</guid>

					<description><![CDATA[In a groundbreaking advancement in pediatric ophthalmology, researchers have unveiled a novel therapeutic strategy that significantly mitigates retinal vasculopathy associated with retinopathy of prematurity (ROP) in an in vivo mouse model. This innovative approach leverages the efficacy of intravitreal bevacizumab nanoparticles, presenting a promising horizon for managing one of the leading causes of childhood blindness [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287408</post-id>	</item>
		<item>
		<title>Innovative Nonsurgical Approach Offers New Hope for Treating Pelvic Organ Prolapse</title>
		<link>https://bioengineer.org/innovative-nonsurgical-approach-offers-new-hope-for-treating-pelvic-organ-prolapse/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 27 Aug 2025 17:23:37 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[Bioengineering Innovations]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Nonsurgical Therapies]]></category>
		<category><![CDATA[Pelvic Organ Prolapse Treatment]]></category>
		<category><![CDATA[Regenerative Medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/innovative-nonsurgical-approach-offers-new-hope-for-treating-pelvic-organ-prolapse/</guid>

					<description><![CDATA[Pelvic organ prolapse (POP) remains a pervasive yet underrecognized condition predominantly affecting older women, particularly those with a history of multiple vaginal births. This disorder arises due to the weakening of the muscles, ligaments, and connective tissues that serve as structural supports for the pelvic organs. The vagina, bladder, uterus, urethra, and rectum depend on [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">258645</post-id>	</item>
		<item>
		<title>Harnessing Low-Intensity Ultrasound to Deliver Targeted Cancer Therapy</title>
		<link>https://bioengineer.org/harnessing-low-intensity-ultrasound-to-deliver-targeted-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 16 Jun 2025 14:25:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Nanoparticle drug delivery]]></category>
		<category><![CDATA[Non-invasive chemotherapy]]></category>
		<category><![CDATA[Sonocatalytic cancer therapy]]></category>
		<category><![CDATA[Targeted cancer immunotherapy]]></category>
		<category><![CDATA[Ultrasound-activated prodrugs]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-low-intensity-ultrasound-to-deliver-targeted-cancer-therapy/</guid>

					<description><![CDATA[In the ongoing battle against cancer, one of the most significant obstacles has been the challenge of delivering effective chemotherapy that can differentiate between malignant and healthy cells. Conventional chemotherapy agents, while potent against tumor cells, often inflict severe collateral damage on healthy tissues, leading to debilitating side effects and sometimes limiting the doses patients [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">249460</post-id>	</item>
	</channel>
</rss>
